MYD88 and bacterial infectious disease: The data show that pharmacological inhibition of MYD88 suppresses osteoclast induction and alveolar bone resorption caused by periodontitis in vivo, thereby suggesting that MYD88 can be a therapeutic target for bone loss due to bacterial infections, including periodontitis.